Beth L. Nordstrom
Beth L. Nordstrom has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Jason C. Simeone
Real-world Evidence, Evidera, Waltham, MA, USA
3 shared publications - Anna Schultze
Department of Non‐communicable Disease Epidemiology London School of Hygiene & Tropical Medicine London UK
2 shared publications Bin Cai
Shionogi Inc., Florham Park, NJ, USA
2 shared publicationsFabio De Gregorio
Shionogi B.V., London, UK
2 shared publicationsHairong Xu
Amgen Inc, One Amgen Center Drive, Thousand Oaks, USA
2 shared publicationsJenna Collins
Evidera, Waltham, USA
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (5) , e250072
Comparative safety of direct oral anticoagulants and low-molecular-weight heparin in patients with venous thromboembolism and cancer in Europe
Aim: This study aimed to compare the safety and effectiveness of direct oral anticoagulants (DOACs) with low-molecular-weight heparin (LMWH) in patients with venous thromboembolism (VTE) and active cancer in a real-world setting in Sweden, Norway, Finland, the UK and Germany. Materials & methods: This observational cohort study used datasets from Sweden, Norway, Finland (National Patient and Prescription Registers) the UK (Clinical Practice Research Datalink and Hospital Episode Statistics) and Germany (AOK Plus and GWQ) from 2013 to 2020. We identified treatment-naive adult patients with cancer-related VTE treated with a DOAC or LMWH. We employed inverse probability of treatment weighting for each DOAC-LMWH comparison and assessed recurrent VTE and bleeding risk (overall and by site: gastrointestinal [GI], intracranial hemorrhage [ICH] or other) within 6 months of treatment initiation. Fine–Gray models were fitted to estimate adjusted hazard ratios and country level estimates were meta-analyzed. Results: After inverse probability of treatment weighting, 30,002 and 2892 patients were included in the LMWH-apixaban comparison, and 29,976 and 4321 in the LMWH-rivaroxaban comparison, respectively. Recurrent VTE could not be assessed comparatively because of low numbers. At 6 months, apixaban was associated with a lower risk of overall and other (HR: 0.67 [95% CI: 0.53,0.86]; 0.64 [0.41,0.998]) bleeding compared with LMWH, with similar risks for GI and ICH bleeding (0.89 [0.61,1.29]; 0.67 [0.31,1.44], respectively). Rivaroxaban had a similar risk of overall, GI, and other bleeding (0.98 [0.83, 1.15]; 0.86 [0.47,1.58]; 0.89 [0.74,1.08]) compared with LMWH, but a lower risk of ICH (0.32 [0.13, 0.82]). Conclusion: These findings suggest that apixaban may offer a safer bleeding profile than LMWH for patients with cancer-associated VTE, particularly in reducing overall and other types of bleeding. Rivaroxaban also appears to be a viable alternative to LMWH, with a notably lower risk of ICH. These results provide valuable real-world insights in an area where evidence remains very limited and support the role of DOACs as a safe alternative to LMWH in patients with VTE and cancer.
- 1 May 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (5) , e250072
Open AccessComparative safety of direct oral anticoagulants and low-molecular-weight heparin in patients with venous thromboembolism and cancer in Europe
Aim: This study aimed to compare the safety and effectiveness of direct oral anticoagulants (DOACs) with low-molecular-weight heparin (LMWH) in patients with venous thromboembolism (VTE) and active cancer in a real-world setting in Sweden, Norway, Finland, the UK and Germany. Materials & methods: This observational cohort study used datasets from Sweden, Norway, Finland (National Patient and Prescription Registers) the UK (Clinical Practice Research Datalink and Hospital Episode Statistics) and Germany (AOK Plus and GWQ) from 2013 to 2020. We identified treatment-naive adult patients with cancer-related VTE treated with a DOAC or LMWH. We employed inverse probability of treatment weighting for each DOAC-LMWH comparison and assessed recurrent VTE and bleeding risk (overall and by site: gastrointestinal [GI], intracranial hemorrhage [ICH] or other) within 6 months of treatment initiation. Fine–Gray models were fitted to estimate adjusted hazard ratios and country level estimates were meta-analyzed. Results: After inverse probability of treatment weighting, 30,002 and 2892 patients were included in the LMWH-apixaban comparison, and 29,976 and 4321 in the LMWH-rivaroxaban comparison, respectively. Recurrent VTE could not be assessed comparatively because of low numbers. At 6 months, apixaban was associated with a lower risk of overall and other (HR: 0.67 [95% CI: 0.53,0.86]; 0.64 [0.41,0.998]) bleeding compared with LMWH, with similar risks for GI and ICH bleeding (0.89 [0.61,1.29]; 0.67 [0.31,1.44], respectively). Rivaroxaban had a similar risk of overall, GI, and other bleeding (0.98 [0.83, 1.15]; 0.86 [0.47,1.58]; 0.89 [0.74,1.08]) compared with LMWH, but a lower risk of ICH (0.32 [0.13, 0.82]). Conclusion: These findings suggest that apixaban may offer a safer bleeding profile than LMWH for patients with cancer-associated VTE, particularly in reducing overall and other types of bleeding. Rivaroxaban also appears to be a viable alternative to LMWH, with a notably lower risk of ICH. These results provide valuable real-world insights in an area where evidence remains very limited and support the role of DOACs as a safe alternative to LMWH in patients with VTE and cancer.
- Open Access
- 1 October 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-15
Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer – a cohort study in US electronic health record data
Background: There are limited real-world data on the prevalence of brain metastases (BM) in metastatic breast cancer (mBC) across the treatment pathway, especially when stratified by human epidermal growth factor receptor 2–positive (HER2+) or HER2–negative (HER2−) status. The goals of this study were to estimate the prevalence of BM at metastatic diagnosis and at the start of each line of systemic therapy (LOT), and to describe treatment patterns and overall survival (OS) in patients with and without BM. Methods: This retrospective cohort study included adult patients in the US with mBC diagnosed between January 2013 − May 2020, with known HER2 status from an electronic health record-derived, deidentified database. Patients were followed from mBC diagnosis to last activity date or death. Descriptive statistics were used for BM prevalence, patient characteristics, and treatment patterns. OS was estimated using the Kaplan-Meier method. Results: Of 12,644 patients with mBC in the database, 1923 (HER2+) and 9693 (HER2−) were included. The prevalence of BM at mBC diagnosis was 12.5% (HER2+) and 1.7% (HER2−). An NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommended systemic treatment for BM was received by 25.0% of patients with BM (HER2+) versus 12.8% (HER2−) during first-line treatment. The prevalence of BM (documented before or within the same month of LOT start) was 11.2%, 22.8%, and 33.0% in those with HER2+ diseases who had at least one, two, and three prior LOTs, respectively. The prevalence of BM among patients with HER2− disease was 1.6%, 2.0%, and 2.8% in those who had at least one, two, and three prior LOTs, respectively. Median OS from mBC diagnosis among patients with versus without BM was 24 versus 37 months (HER2+) and 12 versus 27 months (HER2−). Conclusions: In this real-world study of patients receiving care in US oncology clinics, the prevalence of BM in patients with mBC increased by LOT, and most were not receiving NCCN Guideline®-recommended systemic therapies. OS was poorer in patients with BM versus without BM, especially in the HER2− population. These results highlight a need for more effective treatments for patients with mBC and BM.
- 1 October 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-15
Open AccessEpidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer – a cohort study in US electronic health record data
Background: There are limited real-world data on the prevalence of brain metastases (BM) in metastatic breast cancer (mBC) across the treatment pathway, especially when stratified by human epidermal growth factor receptor 2–positive (HER2+) or HER2–negative (HER2−) status. The goals of this study were to estimate the prevalence of BM at metastatic diagnosis and at the start of each line of systemic therapy (LOT), and to describe treatment patterns and overall survival (OS) in patients with and without BM. Methods: This retrospective cohort study included adult patients in the US with mBC diagnosed between January 2013 − May 2020, with known HER2 status from an electronic health record-derived, deidentified database. Patients were followed from mBC diagnosis to last activity date or death. Descriptive statistics were used for BM prevalence, patient characteristics, and treatment patterns. OS was estimated using the Kaplan-Meier method. Results: Of 12,644 patients with mBC in the database, 1923 (HER2+) and 9693 (HER2−) were included. The prevalence of BM at mBC diagnosis was 12.5% (HER2+) and 1.7% (HER2−). An NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommended systemic treatment for BM was received by 25.0% of patients with BM (HER2+) versus 12.8% (HER2−) during first-line treatment. The prevalence of BM (documented before or within the same month of LOT start) was 11.2%, 22.8%, and 33.0% in those with HER2+ diseases who had at least one, two, and three prior LOTs, respectively. The prevalence of BM among patients with HER2− disease was 1.6%, 2.0%, and 2.8% in those who had at least one, two, and three prior LOTs, respectively. Median OS from mBC diagnosis among patients with versus without BM was 24 versus 37 months (HER2+) and 12 versus 27 months (HER2−). Conclusions: In this real-world study of patients receiving care in US oncology clinics, the prevalence of BM in patients with mBC increased by LOT, and most were not receiving NCCN Guideline®-recommended systemic therapies. OS was poorer in patients with BM versus without BM, especially in the HER2− population. These results highlight a need for more effective treatments for patients with mBC and BM.
- Open Access
- 23 March 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (3) , 102081
Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Renal Cell Carcinoma in England: A Retrospective Cohort Study
- 23 March 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (3) , 102081
Open AccessPatient Characteristics, Treatment Patterns, and Outcomes for Patients With Renal Cell Carcinoma in England: A Retrospective Cohort Study
- Open Access
- 7 February 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (11) , 1343-1355
Treatment Patterns and Outcomes Following Disease Progression on Anti-PD-1 Therapies for Advanced Melanoma
Background: Anti-PD-1-based therapies prolong survival in advanced melanoma, but disease progression is common. This study evaluated treatment patterns and overall survival (OS) after anti-PD-1 pro...
- 7 February 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (11) , 1343-1355
Open AccessTreatment Patterns and Outcomes Following Disease Progression on Anti-PD-1 Therapies for Advanced Melanoma
Background: Anti-PD-1-based therapies prolong survival in advanced melanoma, but disease progression is common. This study evaluated treatment patterns and overall survival (OS) after anti-PD-1 pro...
- Open Access
- 1 January 2022
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 13
Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
Introduction: The primary aim of this study was to compare the incidence of venous thromboembolism (VTE) among women initiating ospemifene vs other selective estrogen receptor modulator (SERM) therapies for estrogen-deficiency conditions or breast cancer prevention, and vs women with untreated vulvar and vaginal atrophy (VVA). The secondary objective examined numerous additional safety outcomes. Methods: This was a retrospective cohort study using the IBM Watson MarketScan claims database. Women receiving ospemifene, another SERM, or with a new diagnosis of VVA with no treatment from 1 May 2013 to 2 October 2018 were followed through the claims for incident adverse outcomes. The primary outcome was the first occurrence of VTE following cohort entry; secondary outcomes included cerebrovascular events and other adverse events potentially associated with SERM use. Cox models compared the risk of VTE between ospemifene and comparators, using a variety of approaches to control for confounding. Results: The incidence of VTE during the first continuous treatment episode was 3.39 (95% confidence interval [CI]: 1.55–6.43) events per 1,000 person-years (PY) for ospemifene ( N = 8977), 11.30 (95% CI: 8.81–14.28) events per 1,000 PY for comparator SERM ( N = 12,621), and 10.92 (95% CI: 10.49–11.37) events per 1,000 PY for untreated VVA ( N = 242,488). Cox models indicated no increase in risk of VTE for ospemifene vs other SERMs (hazard ratio [HR]: 0.40, 95% CI: 0.19–0.82), and vs untreated VVA (HR: 0.47, 95% CI: 0.24–0.91). Conclusion: This real-world safety analysis found no increase in risk of VTE or other adverse events with use of ospemifene in postmenopausal women. Plain Language Summary: Introduction: This study assessed the risk of venous thromboembolism (VTE) among women treated with ospemifene or another selective estrogen receptor modulator (SERM) therapy and women with untreated vulvar and vaginal atrophy (VVA). Numerous additional safety outcomes were examined. Methods: This study was conducted in the IBM Watson MarketScan claims database. Women receiving ospemifene, another SERM, or with a new diagnosis of VVA with no treatment from 1 May 2013 to 2 October 2018 were followed through the claims for adverse outcomes, including VTE, cerebrovascular events (such as stroke), and other outcomes that might occur with use of a SERM. The analyses compared the risk of VTE between ospemifene and the other two groups, using methods that accounted for differences in patient characteristics between the groups. Because few women over 72 years old used ospemifene, the main analyses examined women aged 54–72 years. Results: The analyses included 8,977 ospemifene users, 12,621 other SERM users, and 242,488 women with untreated VVA. Among women aged 54–72 years, only 9 experienced a VTE during ospemifene treatment, while 55 other SERM users and 1,788 women with untreated VVA had a VTE. The analyses that accounted for differences between the groups confirmed that the risk of VTE was no higher in ospemifene users than in either comparison group. Conclusion: This real-world safety analysis found no increase in risk of VTE or other adverse events with use of ospemifene in postmenopausal women.
- 1 January 2022
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 13
Open AccessRisk of venous thromboembolism among women receiving ospemifene: a comparative observational study
Introduction: The primary aim of this study was to compare the incidence of venous thromboembolism (VTE) among women initiating ospemifene vs other selective estrogen receptor modulator (SERM) therapies for estrogen-deficiency conditions or breast cancer prevention, and vs women with untreated vulvar and vaginal atrophy (VVA). The secondary objective examined numerous additional safety outcomes. Methods: This was a retrospective cohort study using the IBM Watson MarketScan claims database. Women receiving ospemifene, another SERM, or with a new diagnosis of VVA with no treatment from 1 May 2013 to 2 October 2018 were followed through the claims for incident adverse outcomes. The primary outcome was the first occurrence of VTE following cohort entry; secondary outcomes included cerebrovascular events and other adverse events potentially associated with SERM use. Cox models compared the risk of VTE between ospemifene and comparators, using a variety of approaches to control for confounding. Results: The incidence of VTE during the first continuous treatment episode was 3.39 (95% confidence interval [CI]: 1.55–6.43) events per 1,000 person-years (PY) for ospemifene ( N = 8977), 11.30 (95% CI: 8.81–14.28) events per 1,000 PY for comparator SERM ( N = 12,621), and 10.92 (95% CI: 10.49–11.37) events per 1,000 PY for untreated VVA ( N = 242,488). Cox models indicated no increase in risk of VTE for ospemifene vs other SERMs (hazard ratio [HR]: 0.40, 95% CI: 0.19–0.82), and vs untreated VVA (HR: 0.47, 95% CI: 0.24–0.91). Conclusion: This real-world safety analysis found no increase in risk of VTE or other adverse events with use of ospemifene in postmenopausal women. Plain Language Summary: Introduction: This study assessed the risk of venous thromboembolism (VTE) among women treated with ospemifene or another selective estrogen receptor modulator (SERM) therapy and women with untreated vulvar and vaginal atrophy (VVA). Numerous additional safety outcomes were examined. Methods: This study was conducted in the IBM Watson MarketScan claims database. Women receiving ospemifene, another SERM, or with a new diagnosis of VVA with no treatment from 1 May 2013 to 2 October 2018 were followed through the claims for adverse outcomes, including VTE, cerebrovascular events (such as stroke), and other outcomes that might occur with use of a SERM. The analyses compared the risk of VTE between ospemifene and the other two groups, using methods that accounted for differences in patient characteristics between the groups. Because few women over 72 years old used ospemifene, the main analyses examined women aged 54–72 years. Results: The analyses included 8,977 ospemifene users, 12,621 other SERM users, and 242,488 women with untreated VVA. Among women aged 54–72 years, only 9 experienced a VTE during ospemifene treatment, while 55 other SERM users and 1,788 women with untreated VVA had a VTE. The analyses that accounted for differences between the groups confirmed that the risk of VTE was no higher in ospemifene users than in either comparison group. Conclusion: This real-world safety analysis found no increase in risk of VTE or other adverse events with use of ospemifene in postmenopausal women.
- Open Access
- 25 July 2021
- Published by Springer Nature in Oncology and Therapy
- Vol. 9 (2) , 575-589
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status
Introduction Limited data exist on real-world treatment patterns and the effectiveness of cyclin-dependent kinase (CDK) 4/6 inhibitors in germline BRCA (gBRCA)-mutated breast cancer. Methods Adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) treated with CDK4/6 inhibitor therapy between 2013 and 2018 were retrospectively selected from the Flatiron Health database. Patients with known gBRCA status were classified as mutated (gBRCAm) or wild type (gBRCAwt). Time-to-first subsequent therapy or death (TFST) and overall survival (OS) were calculated from the earliest line of therapy with a CDK4/6 inhibitor. Results Of 2968 patients with HR+/HER2− mBC receiving a CDK4/6 inhibitor, 859 (28.9%) had known gBRCA status, of whom 9.9% were gBRCAm and 90.1% gBRCAwt. Median (95% confidence interval [CI]) TFST was 10 (7–11) months in the gBRCAm group, 10 (9–11) months in the gBRCAwt group, and 11 (10–12) months in the combined gBRCAwt and unknown gBRCA group; median (95% CI) OS was 26 (21–not estimated), 37 (31–51), and 33 (31–35) months, respectively. Cox models indicated the gBRCAm group had shorter TFST (stratified hazard ratio [sHR] 1.24; 95% CI 0.96–1.59) and OS (sHR 1.50; 95% CI 1.06–2.14) than the gBRCAwt group. The gBRCAm group had shorter TFST (sHR 1.38; 95% CI 1.08–1.75) and OS (sHR 1.22; 95% CI 0.88–1.71) than the combined group. Conclusion The results of this real-world study suggest that treatment outcomes with CDK4/6 inhibitors may be worse in patients with gBRCAm mBC than in their counterparts with gBRCAwt and unknown gBRCA status, suggesting potential differences in tumor biology. This result highlights the unmet need in patients with gBRCAm requiring optimized treatment selection and sequencing. Future exploration in larger samples of patients who have had biomarker testing is warranted.
- 25 July 2021
- Published by Springer Nature in Oncology and Therapy
- Vol. 9 (2) , 575-589
Open AccessA Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status
Introduction Limited data exist on real-world treatment patterns and the effectiveness of cyclin-dependent kinase (CDK) 4/6 inhibitors in germline BRCA (gBRCA)-mutated breast cancer. Methods Adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) treated with CDK4/6 inhibitor therapy between 2013 and 2018 were retrospectively selected from the Flatiron Health database. Patients with known gBRCA status were classified as mutated (gBRCAm) or wild type (gBRCAwt). Time-to-first subsequent therapy or death (TFST) and overall survival (OS) were calculated from the earliest line of therapy with a CDK4/6 inhibitor. Results Of 2968 patients with HR+/HER2− mBC receiving a CDK4/6 inhibitor, 859 (28.9%) had known gBRCA status, of whom 9.9% were gBRCAm and 90.1% gBRCAwt. Median (95% confidence interval [CI]) TFST was 10 (7–11) months in the gBRCAm group, 10 (9–11) months in the gBRCAwt group, and 11 (10–12) months in the combined gBRCAwt and unknown gBRCA group; median (95% CI) OS was 26 (21–not estimated), 37 (31–51), and 33 (31–35) months, respectively. Cox models indicated the gBRCAm group had shorter TFST (stratified hazard ratio [sHR] 1.24; 95% CI 0.96–1.59) and OS (sHR 1.50; 95% CI 1.06–2.14) than the gBRCAwt group. The gBRCAm group had shorter TFST (sHR 1.38; 95% CI 1.08–1.75) and OS (sHR 1.22; 95% CI 0.88–1.71) than the combined group. Conclusion The results of this real-world study suggest that treatment outcomes with CDK4/6 inhibitors may be worse in patients with gBRCAm mBC than in their counterparts with gBRCAwt and unknown gBRCA status, suggesting potential differences in tumor biology. This result highlights the unmet need in patients with gBRCAm requiring optimized treatment selection and sequencing. Future exploration in larger samples of patients who have had biomarker testing is warranted.
- 11 May 2020
- Published by Wolters Kluwer Health in Menopause
- Vol. 27 (8) , 864-871
Incidence of venous thromboembolism among postmenopausal women prescribed ospemifene, selective estrogen receptor modulators for noncancer indications, or untreated vulvar and vaginal atrophy
Objective: Ospemifene is a nonsteroidal selective estrogen receptor modulator (SERM) for the treatment of moderate symptomatic vulvar and vaginal atrophy (VVA) due to menopause. A postauthorization safety study is currently examining the incidence of venous thromboembolism (VTE) among postmenopausal women receiving ospemifene or other SERM (raloxifene, bazedoxifene, or tamoxifen, for noncancer indications), or with untreated VVA. Methods: This interim analysis used the US MarketScan Commercial and Medicare Supplemental claims database from 2013 to 2017 to identify incident VTE. The incidence rate and 95% confidence interval of VTE during the first continuous course of treatment (or continuous untreated time for the untreated cohort) were calculated for each cohort overall and by age group, with sensitivity analyses examining incidence in the short term (up to 90 days) and long term (all available follow-up, regardless of treatment changes). Results: Analyses included 8,188 ospemifene users, 11,777 other SERM users, and 220,242 women with untreated VVA. The incidence per 1,000 person-years and 95% confidence interval of VTE were 3.7 (1.7-7.1) for ospemifene, 11.5 (8.9-14.6) for other SERM, and 11.3 (10.8-11.7) for untreated VVA. Stratification by age and altering the time frame for analysis produced results with similar patterns to the primary analysis. Conclusions: This interim analysis of an ongoing study suggests a favorable safety profile for ospemifene with respect to VTE. Comparative analyses with covariate adjustment will be performed when data accrual is complete.
- 11 May 2020
- Published by Wolters Kluwer Health in Menopause
- Vol. 27 (8) , 864-871
Incidence of venous thromboembolism among postmenopausal women prescribed ospemifene, selective estrogen receptor modulators for noncancer indications, or untreated vulvar and vaginal atrophy
Objective: Ospemifene is a nonsteroidal selective estrogen receptor modulator (SERM) for the treatment of moderate symptomatic vulvar and vaginal atrophy (VVA) due to menopause. A postauthorization safety study is currently examining the incidence of venous thromboembolism (VTE) among postmenopausal women receiving ospemifene or other SERM (raloxifene, bazedoxifene, or tamoxifen, for noncancer indications), or with untreated VVA. Methods: This interim analysis used the US MarketScan Commercial and Medicare Supplemental claims database from 2013 to 2017 to identify incident VTE. The incidence rate and 95% confidence interval of VTE during the first continuous course of treatment (or continuous untreated time for the untreated cohort) were calculated for each cohort overall and by age group, with sensitivity analyses examining incidence in the short term (up to 90 days) and long term (all available follow-up, regardless of treatment changes). Results: Analyses included 8,188 ospemifene users, 11,777 other SERM users, and 220,242 women with untreated VVA. The incidence per 1,000 person-years and 95% confidence interval of VTE were 3.7 (1.7-7.1) for ospemifene, 11.5 (8.9-14.6) for other SERM, and 11.3 (10.8-11.7) for untreated VVA. Stratification by age and altering the time frame for analysis produced results with similar patterns to the primary analysis. Conclusions: This interim analysis of an ongoing study suggests a favorable safety profile for ospemifene with respect to VTE. Comparative analyses with covariate adjustment will be performed when data accrual is complete.
- Open Access
- 28 March 2020
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 8 (2) , 236-245
Burden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England
Background: Data on asthma burden in pediatric patients are limited; this real‐world study investigated exacerbation frequency and health care resource utilization (HCRU) in pediatric asthma patients from the US and England.Methods: Data from pediatric patients (aged 6‐17 years) in the Optum claims database (US) or Clinical Practice Research Datalink with linkage to Hospital Episode Statistics (England) were analyzed. Patients were categorized into four hierarchical groups: treated asthma (patients with ≥1 baseline asthma medication), severe asthma (plus Global Initiative for Asthma Step 4/5), severe refractory asthma ([SRA] plus ≥2 baseline severe asthma exacerbations), and eosinophilic SRA (SRA plus blood eosinophil count ≥150 cells/µL). Exacerbation frequency and HCRU during the 12 months postindex were described.Results: Of 151 549 treated asthma patients in the US, 18 086 had severe asthma, 2099 SRA, and 109 eosinophilic SRA. There were 32 893 treated asthma patients in England, of whom 2711 had severe asthma, 265 SRA, and 8 eosinophilic SRA. In the 12 months postindex, ≥1 exacerbation occurred in 12.4% and 10.8% of patients with severe asthma, and 32.6% and 42.6% with SRA in the US and England, respectively. The proportions of patients with ≥1 asthma hospitalization in the 30 days after the first asthma exacerbation were 2.7% and 4.4% (treated), 3.5% and 8.2% (severe asthma), and 6.0% and 16.8% (SRA) in the US and England, respectively.Conclusion: This study provides insights into current asthma management practices in the US and England and indicates that some patients with severe disease have an unmet need for effective management.
- 28 March 2020
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 8 (2) , 236-245
Open AccessBurden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England
Background: Data on asthma burden in pediatric patients are limited; this real‐world study investigated exacerbation frequency and health care resource utilization (HCRU) in pediatric asthma patients from the US and England.Methods: Data from pediatric patients (aged 6‐17 years) in the Optum claims database (US) or Clinical Practice Research Datalink with linkage to Hospital Episode Statistics (England) were analyzed. Patients were categorized into four hierarchical groups: treated asthma (patients with ≥1 baseline asthma medication), severe asthma (plus Global Initiative for Asthma Step 4/5), severe refractory asthma ([SRA] plus ≥2 baseline severe asthma exacerbations), and eosinophilic SRA (SRA plus blood eosinophil count ≥150 cells/µL). Exacerbation frequency and HCRU during the 12 months postindex were described.Results: Of 151 549 treated asthma patients in the US, 18 086 had severe asthma, 2099 SRA, and 109 eosinophilic SRA. There were 32 893 treated asthma patients in England, of whom 2711 had severe asthma, 265 SRA, and 8 eosinophilic SRA. In the 12 months postindex, ≥1 exacerbation occurred in 12.4% and 10.8% of patients with severe asthma, and 32.6% and 42.6% with SRA in the US and England, respectively. The proportions of patients with ≥1 asthma hospitalization in the 30 days after the first asthma exacerbation were 2.7% and 4.4% (treated), 3.5% and 8.2% (severe asthma), and 6.0% and 16.8% (SRA) in the US and England, respectively.Conclusion: This study provides insights into current asthma management practices in the US and England and indicates that some patients with severe disease have an unmet need for effective management.
- Open Access
- 1 February 2020
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 9 (3) , 191-199
Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison
Aim: To compare the overall survival of patients with metastatic urothelial carcinoma (mUC) who failed platinum-based chemotherapy and received durvalumab or chemotherapy. Patients & methods: In an indirect comparison of patients with mUC who failed platinum-based chemotherapy, those who received durvalumab in a single-arm study were matched to patients from the Flatiron oncology electronic medical record database who received chemotherapy (n = 158 for each cohort). Matching was based on propensity scores. Kaplan–Meier methods and Cox regression models were utilized. Results: Median overall survival was 11.2 months (95% CI: 7.2–16.9) for durvalumab versus 8.2 months (95% CI: 6.7–9.8) for chemotherapy (hazard ratio: 0.63; 95% CI: 0.48–0.84). Conclusion: As a second-line therapy for mUC, durvalumab was associated with longer overall survival than chemotherapy.
- 1 February 2020
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 9 (3) , 191-199
Open AccessEffectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison
Aim: To compare the overall survival of patients with metastatic urothelial carcinoma (mUC) who failed platinum-based chemotherapy and received durvalumab or chemotherapy. Patients & methods: In an indirect comparison of patients with mUC who failed platinum-based chemotherapy, those who received durvalumab in a single-arm study were matched to patients from the Flatiron oncology electronic medical record database who received chemotherapy (n = 158 for each cohort). Matching was based on propensity scores. Kaplan–Meier methods and Cox regression models were utilized. Results: Median overall survival was 11.2 months (95% CI: 7.2–16.9) for durvalumab versus 8.2 months (95% CI: 6.7–9.8) for chemotherapy (hazard ratio: 0.63; 95% CI: 0.48–0.84). Conclusion: As a second-line therapy for mUC, durvalumab was associated with longer overall survival than chemotherapy.
- 1 June 2019
- Published by Elsevier in Cancer Epidemiology
- Vol. 60, 121-127
Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting
- 1 June 2019
- Published by Elsevier in Cancer Epidemiology
- Vol. 60, 121-127
Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting